Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04259255 · ClinicalTrials.gov registry record
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
A clinical trial, sponsored by Shionogi.
- Completed
- Registry status
- 74
- Enrollment target
NCT04259255 is a clinical trial that has completed, run by Shionogi. The registered enrollment target is 74 participants.
The verdict
NCT04259255 has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- 74 participants
- Enrollment target
Study Summary
REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and protein biomarkers will also be investigated.
Interventions
- DRUG Edaravone (Radicava®/Radicava ORS®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2019-10-21 |
| Est. Completion | 2024-11-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04259255
The ClinicalTrials.gov registry entry for NCT04259255 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Edaravone (Radicava®/Radicava ORS®) is the first listed.
NCT04259255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04259255 about?
NCT04259255 is a clinical study titled "Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)". REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and protein biomarkers will also be investigated.
What is the current status of trial NCT04259255?
This trial is currently completed. The enrollment target is 74 participants. The study started on 2019-10-21. Estimated completion is 2024-11-24.
What interventions are being tested in trial NCT04259255?
The interventions under investigation include: Edaravone (Radicava®/Radicava ORS®) (DRUG).
Who is sponsoring clinical trial NCT04259255?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.